Vitamin K, discoveredinthe 1930s,functions as cofactorfor the posttranslational carboxylation of glutamate residues.Gammacarboxy glutamic acid (Gla)-residues were first identified in prothrombin and coagulation factors in the 1970s; subsequently, extra-hepatic Gla proteinsweredescribed,including osteocalcin and matrix Glaprotein (MGP).Impairment of the functionofosteocalcin and MGP duet oi ncomplete carboxylation results in an increasedriskfor developing osteoporosis and vascular calcification, respectively, and is an unexpected side effect of treatment with oral anticoagulants. It is conceivablet hat others ide effects,possible involving growth-arrest-specific gene 6( Gas6) Keywords Vitamin K, matrix Gla protein, osteocalcin,oral anticoagulants, diagnostics proteinwill be identified in forthcomingyears.In healthyindividuals,substantialfractions of osteocalcinand MGPcirculate as incompletelycarboxylatedspecies,indicating thatthe majority of thesei ndividualsi ss ubclinicallyv itamin K-deficient. Potential newapplicationareas forvitamin Kare therefore its use in dietarysupplements and functional foods forhealthyindividualsto preventbone and vascular disease,aswellasfor patientsonoral anticoagulant treatment to offer themp rotection against coumarin-induceds idee ffects and to reduce diet-induced fluctuations in their INR values.
Introduction
The dietarytrace element vitamin Kwas discovered in the early 1930s by the Danish biochemist Henrik Dam. During hisr esearch on the cholesterol metabolisminchickens, Damobserved thatchicks reared on adietfree of sterolsand poor in fatdeveloped large subcutaneous and intramuscularh aemorrhages (1) . Additionally, it wasr eported by McFarlane et al. thatb lood of chicks fed an ether-extracted fish or meatmeal failedtocoagulate on standing overnighti nt he laboratory ( 2) . Initial experiments with additions of lemon juice, cholesterol, cod-liveroil or ascorbica cidt ot he diet failedt op revent haemorrhages (1) . Further testing of different foods,ranging from cereals and seeds to animalo rgans,r evealed that" the antihaemorraghicf actor" wasf at-soluble with one of its richests ources being hog-liver (3) . HendrikDam designatedthis factor as Koagulations vitamin (abbreviated as vitamin K),becauseofits requirement fornormalh aemostasis (3) . Subsequently,Almquista nd Stokstad reported that the haemorrhagic syndrome could be prevented by concentrated extractsofalfalfa as well as by fish meals and bran preparations subjected to the action of microorganisms (4) .
In the mid 1930s, Schønheyderproposed thatthe prolonged clotting time seen in animals with the haemorrhagicsyndrome wasdue to adecreased concentration of plasma prothrombin (5); indeed,precipitatesofprothrombin from the plasma of "K-avitaminous" chicks were found to be inactive (6) and the prothrombin timeofchicks and rabbits fedwith spoiledsweet clover hay -resulting in haemorrhagicdisease-tobeincreased (7, 8) . In later years,itwas establishedthat sweet clover haycontained dicoumarin, avitamin Kantagonist produced by molds acting on the hay (9) .
In the late 1930s several research groups were able to isolate vitamin Kfrom alfalfaasayellowoil (10) (11) (12) (13) ; the group at St. LouisUniversity ledbyEdwardA.Doisy could also isolate vitamin Kf rom putrefiedfish mealsa sacrystalline product and designatedthis productasvitamin K 2 (14, 15) . During this time, the first clinical studieswith administration of vitamin Ktopatients with obstructive jaundiceo rb iliary problems were conducted(16), since it had beenrecognized thatthe bleeding tendencys een in these cases wasr elated to vitamin Kd eficiency (17) . Additionally, vitamin Kwas administered to newborns sufferingfrom haemorrhagic diseaseorwho were found to have a prolongedprothrombin time (18) . In lateryears,the prophylactic treatment of newborns (or their mothers) with vitamin Kgained increasing attention (19 (20, 21) . Damand Doisy received the 1943Nobel prizein Physiology or Medicine fort he discovery of vitamin Ka nd its chemical nature (20) .
Presentlyweknowphylloquinoneasvitamin K 1 ;itoriginates from green leafy plantsand green vegetableswhich areits most important dietary source forhumans. The chemical structureof vitamin K 2 waselucidatedinthe 1960s (22) and revealed thatit consists of afamilyofrelated productsnow known as menaquinones. Menaquinones arem ainlyo fm icrobialo rigina nd their nomenclature is basedonthe number of isoprenoid residues in their side chain. Dietary relevant menaquinones range from menaquinones-4 (MK-4) through menaquinones-10 (MK-10). In the human diet the main sources of menaquinones arec heese, curd, and the Japanese foodn atto. MK-4 is the onlym enaquinone that canb ep roduced in mammaliant issues, where it is formedb yconversion of vitamin K 1 ,MK-7 and possiblyother menaquinones.
Mammals have developedanefficient systemfor recycling vitamin K, whichi st he reason whym inute amountsa re sufficient to coverthe dailyrequirement.Therefore,circulating vitamin Klevelsare low, and accuratedetection techniquesfor vitamin Ki nb lood,t issuesa nd food areo nlya vailablei ns ome specializedlaboratories. Modernvitamin Kassessmentrequires extraction, pre-purification, HPLCanalysis and post-column reduction followedb yf luorescence detection. Althoughs everal scientists have contributedinoptimizing the procedure, Martin Shearer is generallyregarded as the founder of modern vitamin Kanalysis (23) .Analternativetofluorescence detection wasrecently provided by the group of Okano, whousedtandem mass spectrometryasadetection system (24) . The group of Shearer also initiated aw orldwide QualityAssurance /Quality Control scheme togetherw ith our group, enabling participating researchers to comparet heir data and to check the reliability of their system on aregular basis (25) .
Functionofvitamin K
Until 1974, varioushypothesesabout the mechanism of vitamin Kaction were proposed,including arole in mitochondrial electron transportand an inducerofprotein synthesis; the discovery of the unusual amino acid γ -carboxy glutamicacid(Gla) in prothrombina st he producto fv itamin Ka ction in 1974f inally identifiedthe unequivocal role of vitamin Kasacofactor for the posttranslational carboxylation of glutamate residues (26, 27) . These findings triggered the development by the group of Suttie of an in-vitro carboxylase assayi nw hich 14 CO 2 wasi ncorporated into glutamate-containing synthetic peptides ( 28) . More than 15 years ago Stafford and coworkers succeeded in purifying the keyenzyme γ -glutamatecarboxylase (GGCX) (29) ,onlyrecently the purification and amino acids equence of the second keyenzyme in vitamin Kmetabolism, vitamin Kepoxide reductase (VKOR) were reported by twoindependent groups (30, 31) . These data have resultedincloningthe cDNA coding for both proteins in insect expression vectors, whichhas boostedthe molecular researchonthe mechanism of vitamin Kaction (32, 33) .
After the discovery of Gla-residues in prothrombin, the subsequentlyi dentified Gla-proteins were thoseinvolved in blood coagulation: factorsVII, IX and Xasw ellasthe proteins C, S, and Z ( 34) . During this time, the presenceo fc arboxylase was demonstrated in aw ide variety of non-hepatic tissues, ranging from bone to skin (35, 36) . It wasassumedthat the endogenous substrate of carboxylase in these tissues (unidentified Gla-proteins), wasnot involved in blood coagulation. This could imply
Figure1:Matrix Gla-protein is synthesized by vascularsmooth muscle cells (A) and accumulates at areas of calcification in the arterial wall (B).
MatrixGla-protein(MGP) is apotentlocal inhibitor of soft tissue calcification; it contains nine glutamate residues, fiveof which can be carboxylatedinavitamin K-dependent way, resulting in carboxylatedMGP (cMGP). Poor vitamin Kstatustherefore results in synthesis of uncarboxylated MGP(ucMGP).Amajor source of MGPis thearterial wall, where it is synthesizedbyvascular smooth muscle cells (VSMC).A)Asinglehuman VSMCinwhichcMGPisstainedwithconformation-specific antibodies. The cell was growninmedium containing a high concentration of calcium (3.6 mM); itsnucleuswas visualizedby Dapi-staining (blue)and MGP was stainedwithFitc-labeledanti-cMGPantibody (green). MGPiscarboxylated in theendoplasmatic reticulum (dense green staining) andsecreted in vesicularstructures. Magnification 1,000x. B) Theimmunohistochemical localization of ucMGPinacalcified artery. Asection from aperipheralarteryofadiabetic patient was stained withanti-ucMGP-antibodies(red) and counterstainedwithhaematoxylin.Calcificationispresent in the medial layerofthe arterialwall and it can be seen that theinactiveMGP has accumulated at theareaof calcification. A, adventitia; Ca, calcification;I,intima; M, media. Magnification40x. that treatment with oralanticoagulants, known to influencethe carboxylation of coagulation factorsinthe liver, would also impair the carboxylation of these unidentified Gla-proteins in extra-hepatic tissues. Treatment with coumarins could therefore have unwanted, and yetu nknown, side-effectsi nt hese tissues. Indeed our group, whichcontributed to the identification of carboxylase in several tissues, urgedm edical doctorsa lready in 1982toreport possible side-effectsfrom treatment with coumarin-derivatives (37) .
The first extra-hepatic sitesinwhich Gla-proteins have been identifieda nd characterized areb one and cartilage.B one Glaprotein, also known as osteocalcin, wasi dentified in the mid 1970s (38, 39) and presentlyservesasamarker for osteoblastic activity.MatrixGla-protein (MGP),first described in 1983 (40) , is the strongest inhibitor of tissue calcification presentlyknown (Fig. 1) . Its importancefor vascularhealth wasdemonstrated in MGP-deficient animals, whichall diedofmassive arterial calcification within 6-8 weeks after birth (41) . In humans, loss-offunction mutations of MGP result in the Keutel syndrome (42), characterized by abnormalcartilage calcification (43) . In 1971, Keutel et al. first described the syndrome in twosiblings presenting with abnormalc artilage calcification, brachytelephalangism, neural hearing loss and peripheral pulmonary stenosis (44) .Atthe age of 38, one of the twosiblings diedofacuteright heartf ailurea fter several years of obstructive pulmonaryd isease; post-mortem examination revealed calcification of arteries throughoutthe body resulting in pulmonaryarterystenosis and multiple braininfarctions (45) .
It is remarkable thatittook about half acenturyafter the discovery of the relation betweenvitamin Kand blood coagulation before the vital importanceofvitamin Kfor bone and vascular health wasrecognized. It is even moreremarkable thatitisstill not commonlyknown among medicaldoctorsthat vitamin K-dependent proteins not onlyr egulate blood coagulation, buta lso otherp hysiological processesi ncluding bone metabolism (osteocalcin), vascularcalcification (MGP),cellgrowth, and apoptosis (growth-arrest-specific gene 6protein,Gas6) (46) and that, as ac onsequence,o ral anticoagulants mayh aveu ndesirede ffects in extra-hepatic tissues.
Unexpectedsideeffects of oralanticoagulants
Oral anticoagulant therapy is awidely used treatment of subjects with increased thrombosis risk; it is basedonthe dailyintakeof 4-hydroxycoumarins (warfarin, acenocoumarol,p henprocoumon) whichbind to the VKOR enzyme and thus inhibit recycling of vitamin K. Consequently, the carboxylation of coagulation factorsi si nhibited resulting in the formation of inactive,n oncarboxylated species also knowasPIVKAs (proteins induced by vitamin Kabsenceorantagonists). It wasgenerally assumedthat this wasthe onlyeffect of oral anticoagulants. Thediscoveryof newGla-proteins not involved in blood coagulation initiated the searchfor side effects of oralanticoagulant treatment.
Pastoureau et al.showedthat lambs receiving warfarin developedosteopenia within several months (47) , whichisprobably due to the impairedfunction of osteocalcin. Careful analysis of bone mineral density in patients on long-terma nticoagulation revealed thatcoumarin anticoagulants areassociatedwith accelerated bone loss and lowbone mass (48) .Hence, long-termuse of oral anticoagulants is consideredasarisk factor fordeveloping osteoporosis. Similarly,i mpairment of MGPm ust be regarded as arisk factor forarterial calcification. Indeed,two independent studies have demonstrated that subjects on long term anticoagulation have muchmore arterial and heart valvecalcification thananage-and sex-matchedcontrol population (49, 50) . It should be mentioned,however,that the effects in experimental animals were morepronounced thaninhumans, whichmay indicatemore complexregulatorysystems in man. Additionally, exposure to warfarin during the first trimestero fp regnancyc an causewarfarinembryopathy, characterized by punctuate calcifications mainlyinthe axialskeleton, proximalfemursand calcanei, nasalhypoplasia and depression of the nasalbridge (51) . It has beensuggestedthat impairment of MGP'sability to inhibit cartilage calcification, underliest he development of these abnormalities (52, 53) .
These examples demonstrate thatinforthcoming years more side effectsoforal anticoagulants maybeexpected and highlight the importanceo fo thers trategiesf or anticoagulant treatment such as the well known plateletaggregation inhibitors(aspirin, clopidogrel,d ipyridamole), as well as the direct thrombin and factor Xinhibitors.
Combination therapy
Another well recognized disadvantage of oral anticoagulant therapyi si ts instability requiring frequent monitoring.S incet he levelofanticoagulation is abalance between the anticoagulant and the dietary vitamin K, fluctuations of dietaryvitamin Kintakemay lead to INR valuesoutside the therapeutic window. One strategy to overcome this problemistodecreasethe dietaryfluctuations in vitamin Kintake. This wasnot shown to be apractical approach. Alternatively, it hasbeen proposed to increase the vitamin Kintakeinthe formofdietary supplements, and to increase the anticoagulant concordantly (54, 55) . In this waythe fluctuations caused by diet will be small relative to the totalvitamin K intake.M ost studies whichh avea ddressed this point used vitamin K 1 .The potential dangerofgiving K 1 in combination with warfarin,h owever,i st hat K 1 is preferentiallyt aken up by the liver, so thatthe increased warfarin used to compensate forthe high vitamin Kintakewill exhaust the vitamin Ksupplies in the vesselw all, thus increasing the calcification risk.The correctness of this hypothesis wasdemonstrated in rats receiving aK 1 + warfarin treatment and whichdeveloped widespread arterial calcifications within 2-4 weeks (56).K 2 vitamins,o nt he other hand,are equallytransported to extrahepatic tissuesand would thus combine am aximalp rotection against unwanted side effects of oral anticoagulants and ahepatic vitamin Kuptakewhich is sufficient to counteract the diet-induced fluctuations in INR. Consistently, K 2 and notK 1 wasc apable of preventing arterial calcification in the above animalmodel (57) (Fig. 2) .
Recently, it wasdemonstrated in rats thathigh vitamin Kintakewas even capable of inducing regression of pre-formed arterial calcifications (58) . Thetwo K 2 vitamins that arecommercially availableare MK-4 and MK-7. To make aproper choice betweenboth forms, it should be realizedthat MK-4 has avery shorthalf-lifetime (about 1hour),but that the half-life timeof
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MK-7 is much longer (about 3d ays). If taken on ao nce daily basis, MK-4 will thus shows ubstantial circulating and tissue fluctuations, whereas MK-7will accumulategraduallyand reach asteady state levelafter 2weeks (59) .Based on these considerations we have recently proposedthat trials will be designedin whichpatients receive coumarinanticoagulants in combination with MK-7. These patients should be followedwith respect to the stability of their INR value in time,aswellasthe development of bonem ineral density and vascularc haracteristics and calcification (60).
K-statusinhealthy adults
As comparedwith othervitamins, the dietary intake of vitamin K is very low. The recommended dietarya llowance (RDA) is 1µg/kg/day. Also, itsbiological half-lifetime is relativelyshort: upon deprivation experimental animals develop symptoms of vitamin K-deficiencywithin afew days. Ye t, vitamin Kintakeis sufficient to ensuren ormal haemostasis in healthya dults.I t should be kept in mind,h owever,t hat the liver-w hich is the placeofclotting factor synthesis -iscapable of extracting vitamin Kf ormt he circulation very efficiently.T herefore,i ti s questionable whether the present RDAf or vitamin Ki ntakei s sufficient to coverthe requirements of extrahepatic tissues.
Conformation-specifica ntibodies aren ow commercially availablespecificallyrecognizing under-carboxylated species of osteocalcin (Takara Shuzo, Shiga,Japan)and MGP (VitaK BV, Maastricht, the Netherlands) whichare generated in subclinical vitamin Kdeficiency. Using these antibodies,ELISA-based assays were developedfor testing circulating under-carboxylated species of osteocalcin and MGP.Surprisingly, these tests showed thatinall apparentlyhealthysubjects tested,asubstantial fraction of both proteins occursinunder-carboxylated forms, which have no biologicala ctivity (61,6 2) . This raises the intriguing question of whether all(or: most)apparentlyhealthyadults are subclinicallyvitamin Kdeficient. Increased circulating levels of undercarboxylated osteocalcin were showntobeassociatedwith increased bone loss and osteoporosis in postmenopausal women (63) , whereas under-carboxylated MGP has beena ssociated witharterial calcification (64).
Newapplication areasfor vitamin K
As mentioned above,extra-hepaticGla-proteins are incompletely carboxylatedinthe majorityofthe healthy adults. Hencethe biological activityofthese proteinsissub-optimal. Onlyinvitamin K-supplemented subjects thep lasma levelo fn on-carboxylated osteocalcin (61, 65, 66) andMGP is below5%ofthe total antigen (Cranenburge ta l., unpublished observations). Thesef indings suggest that, although the dietaryvitamin Kintake is adequate to maintain normal haemostasis,itmay be insufficientfor extrahepatic tissues.I ndeed,t he present dietary reference values are based on aproper functioning of the blood carboxylation factors, andnot on the carboxylation of osteocalcinorMGP.
Poor vitaminKstatus mustberegardedasaserious risk factor for increased postmenopausal bone lossa nd for arteryc alcification, notablyi nd iabetes, endstage renald isease anda ging. Population-based studiesh aved emonstrated an inversec orrelation between dietary vitaminKintakeand bone fracture risk (67) as well as betweendietary vitaminKintakeand arterial calcificationand cardiovascular mortality (68) .Notablyfor vascular health, K 2 appeared to be superior to K 1 .S everal clinical trials have demonstrated that supplementary vitaminKmayresultindecreased bone loss (69) , as well as in maintenance of bone strength (61) andcarotidarteryelasticity (70) .For K 1 andMK-4these effects have been reporteda tp harmacological doses ranging between 1and 45 milligrams perday.Onthe basisofits longer halflife time and extra-hepatic tissuedistributionitistobeexpected that similar effects will be obtained with MK-7atnutritionaldoses (i.e.belowthe RDAfor vitaminK) (59) . Therefore, MK-7 is the obvious choicefor enrichment of dietary supplements andfunctional foodstobeused for disease prevention in healthy subjects.
The third extrahepatic Gla-protein receiving increasing attention is Gas6. Gas6 exhibitsabroadrangeofregulatoryfunctions associated with cell growth regulation, migration and proliferation, cells urvival, apoptosis, recognition of dyingc ells, phagocytosis and celladhesion (71) .Ithas a43%aminoacidse-quence identity (including the 11 Gla residues) with protein S, whichisknown as anegativeregulator of blood coagulation. In contrast to Gas6, protein Salso bindstothe C4b-binding protein, whicha ctsa sanegative regulator of the complement system. Gas6 serves as aligand forasubfamilyofreceptor tyrosinekinases, and it hasb een demonstrated thati ncomplete carboxylation resultsinloss of biologicalactivity (72) . Consequently,interfering with its Gla-content by using coumarin derivativesmay influencethe progressofawidevarietyofpathologiesincluding cancer, cardiovasculard isease, neurological diseases,a utoimmune disease and kidneyd isorders. Conformation-specific antibodiesf or Gas6 have not yetb een described,a nd it is unknown whether also in this casepartiallycarboxylated or uncarboxylated species occur in healthya dults.H owever,w ew ould expectthat the carboxylation status of Gas6 is substantiallydecreased by using oralanticoagulants; this mayaffect the course of diseases such as those mentioned above in an as yetunpredictable way. Once again, oral anticoagulants maysurprise us with unexpected side effects although theyhavebeen widelyusedfor more than 50 years.
Circulating MGP as adiagnostic marker for cardiovasculardisease
MGP is expressed in cartilage and the vasculature.Inhealthytissuesthe expression is relatively low, butaround ectopiccalcifications in the arteries MGPe xpression is up-regulated several orders of magnitude,probably as adefence mechanism triggered by the calcium crystals (73) . Since matureM GP contains five Gla residues per molecule, hypotheticallyt he localv itamin K requirement aroundc alcified lesionsi ss trongly increased,s o thatthe vasculartissue is rapidlydepleted of vitamin K. Hence, at these sitesincompletely carboxylated MGP species areformed (Fig. 1B) , whicha re notf unctional. Whether increased vitamin Kintakemay protect against further calcification is amajor point of interest at this time.Several test kits for MGPinserum and plasma are presently available, and the first datasuggest that circulating MGP total antigen maybecomeamarker forcardiovasculard isease ( 62, 64) . Since MGP mayc irculatei na tl east fourd ifferent conformations,i tr emains to be seen whicht est willprove to have the highestdiagnostic utility.
Conformation-specifica ntibodies against carboxylated and non-carboxylated MGP aren ow available, and with ELISAbased techniquesboth species have beenfound in the circulation (ECM Cranenburge ta l., submittedf or publication). Whereas the absolute levels of eithero ft hese forms mayd ependo na number of factorsincluding vascularsmooth muscle cellactivity,triggered up-regulation of MGPexpression and cellular secretion of the different MGP fractions and localbindinginand around the calcified tissue, the ratio betweencarboxylated and non-carboxylated MGP species will reflect vascularvitamin K status, and thus the extent to whicha ni ndividual is protected againstarterial calcification by the MGP-dependentpathway.
Obviously,t he availability of tests with whicht he vascular vitamin Kstatus can be testedinasmall amount of blood is of major importancefor the health food industry.Lateral flow tests are nowbeing developedfor carboxylated and non-carboxylated MGP; such tests mayb eu sedf or point-of-care or even home diagnosticsproviding information to the consumerabout his/her vitamin Ks tatus and the potentialb enefit of taking vitamin K supplements. By monitoring MGP carboxylation on aregularly basis, this system would provide aunique possibilitytovisualize short-term benefits of vitamin supplements. Withoutdoubt, such asystem should not be brought to the marketbefore the health benefits of nutritionald oses of supplementalv itamin Kh ave beenconfirmed in long-termclinical trials.
